12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial
Lynce F, Brasó-Maristany F, Waks A, Gonzalez P, Villacampa G, Torres E, Galván P, Brunet L, Anderson L, Perou C, Parker J, Vivancos A, Dilullo M, Simon S, Winer E, Overmoyer B, Mittendorf E, Prat A, Tolaney S. 12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial. ESMO Open 2023, 8: 101236. DOI: 10.1016/j.esmoop.2023.101236.Peer-Reviewed Original ResearchInflammatory breast cancerHER2-positive inflammatory breast cancerPhase II clinical trialClinical trialsBreast cancerCorrelative analysisCancerTrials